Association Endorses ENACT Act to Improve Clinical Trial Diversity

Association Endorses ENACT Act to Improve Clinical Trial Diversity

294897

Association Endorses ENACT Act to Improve Clinical Trial Diversity

The Alzheimer’s Association and its advocacy affiliate, the Alzheimer’s Impact Movement (AIM), are backing recently introduced bipartisan legislation to support equity in Alzheimer’s disease clinical trials. The Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act of 2021 (H.R. 3085/S. 1548) would amend the Public Health Service Act to improve the diversity of participants in clinical trials, which is important in treatment development, advocates say. “Alzheimer’s and other dementia disproportionately affect older Black and Hispanic-Americans…

You must be logged in to read/download the full post.